Kase Satoru, Namba Kenichi, Iwata Daiju, Mizuuchi Kazuomi, Ito Takako, Hase Keitaro, Suzuki Kayo, Onozawa Masahiro, Kitaichi Nobuyoshi, Ishida Susumu
Department of Ophthalmology, Faculty of Medicine andGraduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Hematology, Faculty of Medicine and GraduateSchool of Medicine, Hokkaido University, Sapporo, Japan.
Cancer Diagn Progn. 2021 May 3;1(2):69-75. doi: 10.21873/cdp.10010. eCollection 2021 May-Jun.
BACKGROUND/AIM: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL).
Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement.
Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation.
Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period.
背景/目的：本研究旨在阐述原发性玻璃体视网膜淋巴瘤（PVRL）的临床结局。
本研究纳入了17例在北海道大学医院接受治疗的PVRL患者。他们依据细胞学、白细胞介素-10/-6比值以及免疫球蛋白重链（IgH）基因重排进行诊断。
诊断检测在14例（82.3%）患者中发现细胞学恶性特征，在16例（94.1%）患者中发现白细胞介素-10/-6比值升高，在13例（76.5%）患者中发现IgH单克隆性。7例（41.2%）患者在诊断PVRL之前接受了全身糖皮质激素治疗。诊断后的治疗分别包括对11例、7例和5例患者进行玻璃体内甲氨蝶呤注射、局部放疗以及静脉化疗。分别在9例和1例患者中观察到中枢神经系统和全身受累，这些并发症在初次眼部表现后的3至43个月（平均=16个月）出现。
我们的许多患者未接受任何全身干预，并且几乎一半的PVRL患者在随访期间出现中枢神经系统受累。
